Simultaneous quantification of intracellular and secreted active and inactive glucagon-like peptide-1 from cultured cells

Analytical Biochemistry

Volumn 472, Issue , 2015, Pages 45-51

  Amao, Michiko ^a   Kitahara, Yoshiro ^a   Tokunaga, Ayaka ^a   Shimbo, Kazutaka ^a   Eto, Yuzuru ^a   Yamada, Naoyuki ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Absolute quantification; Glucagon like peptide 1; Incretin; LC MS MS; Secretopeptidome; Selected reaction monitoring

Indexed keywords

AMIDES; CELLS; CYTOLOGY; GLUCOSE; HORMONES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; SUGAR SUBSTITUTES;

ABSOLUTE QUANTIFICATION; GLUCAGON-LIKE PEPTIDE-1; INCRETIN; LC-MS/MS; SECRETOPEPTIDOME; SELECTED REACTION MONITORING;

PEPTIDES;

GLUCAGON LIKE PEPTIDE 1 1 37; GLUCAGON LIKE PEPTIDE 1 7 37; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; NATEGLINIDE; PROPROTEIN CONVERTASE 1; SUCRALOSE; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1;

ANALYTIC METHOD; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENTEROENDOCRINE CELL; HORMONAL REGULATION; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MOLECULE; NCI H716 CELL LINE; PEPTIDE ANALYSIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN SECRETION; SELECTED REACTION MONITORING ASSAY; SUPERNATANT; TANDEM MASS SPECTROMETRY; CELL LINE; MASS SPECTROMETRY; PROCEDURES; PROTEOMICS; SECRETION (PROCESS);

CELL LINE; CHROMATOGRAPHY, LIQUID; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84921033618     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2014.11.009     Document Type: Article

References (38)

1. C. Orskov, Glucagon-like peptide-1, a new hormone of the entero-insular axis, Diabetologia 35 (1992) 701-711.
2. L.B. Knudsen, Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes, J. Med. Chem. 47 (2004) 4128-4134.
3. C.F. Deacon, Circulation and degradation of GIP and GLP-1, Horm. Metab. Res. 36 (2004) 761-765.
4. J.E. Campbell, D.J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone action, Cell Metab. 17 (2013) 819-837.
5. C. Ørskov, L. Rabenhøj, A. Wettergren, H. Kofod, J.J. Holst, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes 43 (1994) 535-539.
6. T.J. Kieffer, J. Francis, Habener, the glucagon-like peptides, Endocr. Rev. 20 (1999) 876-913.
7. T.P. Vahl, B.W. Paty, B.D. Fuller, R.L. Prigeon, D.A. D'Alessio, Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans, J. Clin. Endocrinol. Metab. 88 (2003) 1772-1779.
8. T.J. Kieffer, C.H. McIntosh, R.A. Pederson, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology 136 (1995) 3585-3596.
9. R. Mentlein, B. Gallwitz, W.E. Schmidt, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine, and is responsible for their degradation in human serum, Eur. J. Biochem. 214 (1993) 829-835.
10. N.A. Duffy, B.D. Green, N. Irwin, V.A. Gault, A.M. McKillop, F.P.M. O'Harte, P.R. Flatt, Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1, Eur. J. Pharmacol. 568 (2007) 278-286.
11. A.M. McKillop, N.A. Duffy, J.R. Lindsay, B.D. Green, S. Patterson, F.P.M. O'Harte, P.M. Bell, P.R. Flatt, Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation, Eur. J. Endocrinol. 161 (2009) 877-885.
12. R.P. Pauly, F. Rosche, M. Wermann, C.H.S. McIntosh, R.A. Pederson, H.-U. Demuth, Investigation of glucose-dependent insulinotropic polypeptide(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach, J. Biol. Chem. 271 (1996) 23222-23229.
13. S.E. Nikoulina, N.L. Andon, K.M. McCowen, M.D. Hendricks, C. Lowe, S.W. Taylor, A primary colonic crypt model enriched in enteroendocrine cells facilitates a peptidomic survey of regulated hormone secretion, Mol. Cell. Proteomics 9 (2010) 728-741.
14. 3-42 from human plasma samples: new sensitive method to analyze physiological concentrations of peptide hormones, J. Chromatogr. A 926 (2001) 21-27.
15. R. Wolf, T. Hoffmann, F. Rosche, H.-U. Demuth, Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry, J. Chromatogr. B 803 (2004) 91-99.
16. N. Murao, M. Ishigai, H. Yasuno, Y. Shimonaka, Y. Aso, Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up, Rapid Commun. Mass Spectrom. 21 (2007) 4033-4038.
17. P. Shipkova, D.M. Drexler, R. Langish, J. Smalley, M.E. Salyan, M. Sanders, Application of ion trap technology to liquid chromatography/mass spectrometry quantitation of large peptides, Rapid Commun. Mass Spectrom. 22 (2008) 1359-1366.
18. 3-42 in mouse plasma by LC/ESI-MS/MS: preclinical evaluation of DP-IV inhibitors, J. Proteome Res. 8 (2009) 3487-3496.
19. A. Chambery, V. Severino, A. Di Maro, A. D'Aniello, M. Ruvo, A. Parente, Quantification of thyrotropin-releasing hormone by liquid chromatography-electrospray mass spectrometry, Amino Acids 38 (2010) 1031-1041.
20. M.F. Lopez, T. Rezai, D.A. Sarracino, A. Prakash, B. Krastins, M. Athanas, R.J. Singh, D.R. Barnidge, P. Oran, C. Borges, R.W. Nelson, Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants, Clin. Chem. 56 (2010) 281-290.
21. R. Kay, D.J. Halsall, A.K. Annamalai, N. Kandasamy, K. Taylor, S. Fenwick, A. Webb, G. Wark, S. Pleasance, M. Gurnell, A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly, Clin. Endocrinol. 78 (2013) 424-430.
22. 3-42 in human plasma using LC-MS/MS/MS, J. Proteome Res. 12 (2013) 2690-2699.
23. R.A. Reimer, C. Darimont, S. Gremlich, V. Nicolas-Métral, U.T. Rüegg, K. Macé, A human cellular model for studying the regulation of glucagon-like peptide-1 secretion, Endocrinology 142 (2001) 4522-4528.
24. R. Yuji, N. Yamada, N. Arashida, E. Suzuki, K. Hirayama, A robust nanoESI technique for proteome analysis using 30 μm internal diameter tapered stainless-steel needle as an ESI emitter, Seikagaku 75 (2003).
25. A. Kawakami, K. Kubota, N. Yamada, U. Tagami, K. Takehana, I. Sonaka, E. Suzuki, K. Hirayama, Identification and characterization of oxidized human serum albumin, FEBS J. 273 (2006) 3346-3357.
26. K. Sasaki, Y. Satomi, T. Takao, N. Minamino, Snapshot peptidomics of the regulated secretory pathway, Mol. Cell. Proteomics 8 (2009) 1638-1647.
27. K. Sasaki, N. Takahashi, M. Satoh, M. Yamasaki, N. Minamino, A peptidomics strategy for discovering endogenous bioactive peptides, J. Proteome Res. 9 (2010) 5047-5052.
28. K. Sasaki, T. Osaki, N. Minamino, Large-scale identification of endogenous secretory peptides using electron transfer dissociation mass spectrometry, Mol. Cell. Proteomics 12 (2013) 700-709.
29. B.C. Searle, Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies, Proteomics 10 (2010) 1265-1269.
30. ATP channel-independent mechanism, Biol. Pharm. Bull. 34 (2011) 671-676.
31. 42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls, J. Alzheimers Dis. 33 (2013) 1021-1032.
32. H.-J. Jang, Z. Kokrashvili, M.J. Theodorakis, O.D. Carlson, B.-J. Kim, J. Zhou, H.H. Kim, X. Xu, S.L. Chan, M. Juhaszova, M. Bernier, B. Mosinger, R.F. Margolskee, J.M. Egan, Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 15069-15074.
33. I. van den Broek, R.W. Sparidans, J.H.M. Schellens, J.H. Beijnen, Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry, J. Chromatogr. B 872 (2008) 1-22.
34. R. Goda, N. Kobayashi, Evaluation of peptide adsorption-controlled liquid chromatography-tandem mass spectrometric (PAC-LC-MS/MS) method for simple and simultaneous quantitation of amyloid β 1-38, 1-40, 1-42, and 1-43 peptides in dog cerebrospinal fluid, J. Chromatogr. B 895-896 (2012) 137-145.
35. A.M. Rowzee, N.X. Cawley, J.A. Chiorini, G. Di Pasquale, Glucagon-like peptide-1 gene therapy, Exp. Diab. Res. 2011 (2011) 5.
36. A. Suzuki, H. Nakauchi, H. Taniguchi, Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells, Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5034-5039.
37. L. Zhao, H. Ye, D. Li, X. Lao, J. Li, Z. Wang, L. Xiao, Z. Wu, J. Huang, Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice, Regul. Pept. 178 (2012) 1-5.
38. W. Ip, W. Shao, Y.T. Chiang, T. Jin, GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice, Am. J. Physiol. Endocrinol. Metab. 305 (2013) E1348-1358.